10-QPeriod: Q1 FY2006

ALNYLAM PHARMACEUTICALS, INC. Quarterly Report for Q1 Ended Mar 31, 2006

Filed May 9, 2006For Securities:ALNY

Summary

This 10-Q filing for Alnylam Pharmaceuticals, Inc. (ALNY) for the period ending March 31, 2006, provides an unaudited snapshot of the company's financial position and operational results. As a clinical-stage biopharmaceutical company, Alnylam's financial performance is primarily driven by its research and development activities and its ability to secure funding for its pipeline. Investors should pay close attention to the company's cash burn rate, its progress in advancing its RNA interference (RNAi) therapeutics, and its strategic partnerships, which are crucial for future revenue generation. The filing includes unaudited condensed consolidated financial statements, including the balance sheets, statements of operations and comprehensive loss, and cash flows. The Management's Discussion and Analysis section will offer insights into the company's financial condition, results of operations, and market risk. Key risk factors will also be detailed, providing investors with a clear understanding of the potential challenges and uncertainties the company faces.

Key Highlights

  • 1Alnylam Pharmaceuticals, Inc. (ALNY) filed its quarterly report for the period ending March 31, 2006.
  • 2The report contains unaudited condensed consolidated financial statements for balance sheets, operations, and cash flows.
  • 3Investors can find detailed analysis of the company's financial condition and results of operations in the Management's Discussion and Analysis (MD&A) section.
  • 4The filing includes quantitative and qualitative disclosures about market risk.
  • 5Risk factors associated with the company's business and operations are explicitly outlined in the report.
  • 6The report covers the financial performance for the three months ended March 31, 2006, compared to the same period in 2005.

Frequently Asked Questions

As a clinical-stage biopharmaceutical company, Alnylam's primary focus in this period is on the research and development of its RNA interference (RNAi) therapeutics pipeline. This involves advancing its drug candidates through clinical trials and pursuing strategic collaborations.

Information regarding Alnylam's financial health and cash position can be found in the 'CONDENSED CONSOLIDATED BALANCE SHEETS' and 'CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS' within the financial statements section, as well as in the 'MANAGEMEN'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS'.

Key risks for investors are detailed in 'ITEM 1A. RISK FACTORS'. These typically include risks related to the clinical development of novel therapeutics, regulatory approvals, intellectual property, competition, financing requirements, and the inherent uncertainties of the biotechnology industry.

The 'CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS FOR THE THREE MONTHS ENDED MARCH 31, 2006 AND 2005' provides a comparative analysis of the company's revenue, expenses, and net loss for these two periods. Investors should review this section for insights into revenue growth, R&D spending trends, and overall profitability.